Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed a registration statement on Form F-4 with the Securities and Exchange Commission (the "SEC") that includes a preliminary management circular/prospectus and other relevant documents related to various proposals contained therein, and has plans to hold a Special Meeting of Shareholders (the "Special Meeting") to vote on, among other things, a series of transactions that will change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States of America (the "Domestication"). In order to facilitate the Domestication, the Company expects to, prior to the Domestication, continue its existence from the Province of Alberta to the Province of British Columbia (the "Continuance"). The Continuance and the Domestication require approval by the affirmative vote of not less than two-thirds of the votes cast at the Special Meeting by proxy or in person. If approved, the Domestication is expected to occur on January 1, 2026, or as soon as practicable thereafter. There are not expected to be any material changes to the Company's operations or financial results as a result of the Continuance or Domestication. The Company will continue to be subject to SEC reporting requirements and, as applicable, Canadian securities laws, and its common equity securities will continue to trade on the Nasdaq Capital Market under the symbol "ONCY."

Read more at prnewswire.com